We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

European shares ended lower on Wednesday, following a broad rally earlier in the session, hurt by a drop in utilities shares ...

European Union antitrust regulators will decide by Dec. 6 whether ... underscores Novo Nordisk’s push to boost output of its ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA).

Ozempic and Wegovy may not have been developed if not for the insistence of Novo Nordisk's head of research, Mads Krogsgaard. Leadership at the Danish company in the early 1990s were skeptical ...